These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Rapid recovery in mice after combined nasal/oral immunization with killed respiratory syncytial virus. Reuman PD, Keely SP, Schiff GM. J Med Virol; 1990 Sep; 32(1):67-72. PubMed ID: 2243208 [Abstract] [Full Text] [Related]
5. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A. Vaccine; 2013 Apr 19; 31(17):2169-76. PubMed ID: 23499594 [Abstract] [Full Text] [Related]
6. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants. Murphy BR, Collins PL, Lawrence L, Zubak J, Chanock RM, Prince GA. J Gen Virol; 1989 Aug 19; 70 ( Pt 8)():2185-90. PubMed ID: 2671259 [Abstract] [Full Text] [Related]
13. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP. Antimicrob Agents Chemother; 1994 Dec 01; 38(12):2785-91. PubMed ID: 7695263 [Abstract] [Full Text] [Related]
14. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. Johnson PR, Olmsted RA, Prince GA, Murphy BR, Alling DW, Walsh EE, Collins PL. J Virol; 1987 Oct 01; 61(10):3163-6. PubMed ID: 3305988 [Abstract] [Full Text] [Related]